GT Biopharma shares surge 10.83% premarket after submitting IND application for GTB-5550 targeting B7-H3 expressing solid tumors.

GT Biopharma (NASDAQ: GTBP) rose 10.83% in premarket trading following the announcement of an IND submission for GTB-5550 TriKE, a B7-H3-targeted natural killer (NK) cell engager for solid tumor cancers. The submission, completed in December 2025, marks a key regulatory milestone as the company advances its TriKE platform into new indications. Management highlighted that GTB-5550 targets a segment of the $362 billion global solid tumor market and plans a Phase 1 basket trial in 2026. Additionally, the company reported a preliminary cash balance of ~$7 million as of December 31, 2025, extending its runway into Q3 2026, which reinforced investor confidence in its near-term operational flexibility. The news aligns with the stock’s bullish premarket move, driven by progress in its immuno-oncology pipeline and financial stability.